Abstract
Prostate cancer is one of the most common malignancies in old males. While chemotherapy remains an effective method for metastatic castration resistant prostate cancer (mCRPC), most patients develop chemo-resistance with median survival less than 1 year after six to eight cycles of systematic chemotherapy. Therefore, it is very important to elucidate the mechanisms of CRPC and chemotherapy resistance. This article is to focus on the androgen receptor signaling pathway, micro-RNA, tumor microenvironment, cancer stem cells as well as related molecular events, and to summarize the research progress. Key words: Castration resistant prostate cancer; Chemotherapy resistance; Mechanism
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
